264 related articles for article (PubMed ID: 33571540)
1. The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling.
Teng F; Jiang J; Zhang J; Yuan Y; Li K; Zhou B; Zhou X; Liu W; Zhang P; Liu D; Zheng M; Lu Y; Zhang H
Metabolism; 2021 Apr; 117():154725. PubMed ID: 33571540
[TBL] [Abstract][Full Text] [Related]
2. S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis.
Zhang L; Zhang Z; Li C; Zhu T; Gao J; Zhou H; Zheng Y; Chang Q; Wang M; Wu J; Ran L; Wu Y; Miao H; Zou X; Liang B
Cell Mol Gastroenterol Hepatol; 2021; 11(3):697-724. PubMed ID: 33075563
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
[TBL] [Abstract][Full Text] [Related]
4. Hepatic mTOR-AKT2-Insig2 signaling pathway contributes to the improvement of hepatic steatosis after Roux-en-Y Gastric Bypass in mice.
Pan Q; Qin T; Gao Y; Li S; Li D; Peng M; Zhai H; Xu G
Biochim Biophys Acta Mol Basis Dis; 2019 Mar; 1865(3):525-534. PubMed ID: 30562559
[TBL] [Abstract][Full Text] [Related]
5. Caveolin-1 alleviates lipid accumulation in NAFLD associated with promoting autophagy by inhibiting the Akt/mTOR pathway.
Xue W; Wang J; Jiang W; Shi C; Wang X; Huang Y; Hu C
Eur J Pharmacol; 2020 Mar; 871():172910. PubMed ID: 31926991
[TBL] [Abstract][Full Text] [Related]
6. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway.
Chen J; Chen J; Huang J; Li Z; Gong Y; Zou B; Liu X; Ding L; Li P; Zhu Z; Zhang B; Guo H; Cai C; Li J
Aging (Albany NY); 2019 Dec; 11(23):10839-10860. PubMed ID: 31796646
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis.
Zhang M; Chi X; Qu N; Wang C
Biochem Biophys Res Commun; 2018 Apr; 499(1):66-70. PubMed ID: 29555473
[TBL] [Abstract][Full Text] [Related]
8. Long Noncoding RNA lncSHGL Recruits hnRNPA1 to Suppress Hepatic Gluconeogenesis and Lipogenesis.
Wang J; Yang W; Chen Z; Chen J; Meng Y; Feng B; Sun L; Dou L; Li J; Cui Q; Yang J
Diabetes; 2018 Apr; 67(4):581-593. PubMed ID: 29382663
[TBL] [Abstract][Full Text] [Related]
9. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.
Sobolewski C; Abegg D; Berthou F; Dolicka D; Calo N; Sempoux C; Fournier M; Maeder C; Ay AS; Clavien PA; Humar B; Dufour JF; Adibekian A; Foti M
Gut; 2020 Oct; 69(10):1841-1854. PubMed ID: 31919231
[TBL] [Abstract][Full Text] [Related]
10. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
11. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
[TBL] [Abstract][Full Text] [Related]
12. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease.
Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL
Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394
[TBL] [Abstract][Full Text] [Related]
13. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
14. Liver sympathetic denervation reverses obesity-induced hepatic steatosis.
Hurr C; Simonyan H; Morgan DA; Rahmouni K; Young CN
J Physiol; 2019 Sep; 597(17):4565-4580. PubMed ID: 31278754
[TBL] [Abstract][Full Text] [Related]
15. Tranilast Blocks the Interaction between the Protein S100A11 and Receptor for Advanced Glycation End Products (RAGE) V Domain and Inhibits Cell Proliferation.
Huang YK; Chou RH; Yu C
J Biol Chem; 2016 Jul; 291(27):14300-14310. PubMed ID: 27226584
[TBL] [Abstract][Full Text] [Related]
16. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.
He Q; Sha S; Sun L; Zhang J; Dong M
Biochem Biophys Res Commun; 2016 Aug; 476(4):196-203. PubMed ID: 27208776
[TBL] [Abstract][Full Text] [Related]
18.
Shi Y; Pizzini J; Wang H; Das F; Abdul Azees PA; Ghosh Choudhury G; Barnes JL; Zang M; Weintraub ST; Yeh CK; Katz MS; Kamat A
Am J Physiol Endocrinol Metab; 2021 Jul; 321(1):E90-E104. PubMed ID: 34029162
[TBL] [Abstract][Full Text] [Related]
19. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis.
Serrano-Maciá M; Simón J; González-Rellan MJ; Azkargorta M; Goikoetxea-Usandizaga N; Lopitz-Otsoa F; De Urturi DS; Rodríguez-Agudo R; Lachiondo-Ortega S; Mercado-Gomez M; Gutiérrez de Juan V; Bizkarguenaga M; Fernández-Ramos D; Buque X; Baselli GA; Valenti LVC; Iruzubieta P; Crespo J; Villa E; Banales JM; Avila MA; Marin JJG; Aspichueta P; Sutherland J; Barrio R; Mayor U; Elortza F; Xirodimas DP; Nogueiras R; Delgado TC; Martínez-Chantar ML
Mol Metab; 2021 Nov; 53():101275. PubMed ID: 34153521
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
